热门资讯> 正文
阿斯利康、第一三共在晚期乳腺癌研究中取得成功
2025-10-07 01:47
- AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said that its late-stage study of Datroway (datopotamab deruxtecan), being evaluated as a first-line treatment for patients with triple-negative breast cancer, met main goals.
- The study demonstrated a significant and meaningful improvement in dual main goals: overall survival and progression-free survival.
- These results were compared to the standard chemotherapy options for patients with locally recurrent inoperable or metastatic triple-negative breast cancer who were not candidates for immunotherapy.
- The company said that the safety profile of Datroway was consistent with previous clinical trials in breast cancer.
More on AstraZeneca
- AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
- AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy
- AstraZeneca: Buy This Pharma Star Now For Upside Potential
- Pfizer – TrumpRx deal boosts Big Pharma to a record rally
- Trump holding off on pharma tariffs to negotiate more deals - report
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
